EMA’s PRIME Sees New Targets, More Approvals But Few Fast-Track Reviews

 
• By Neena Brizmohun
  
Advanced therapies continue to dominate the types of substances entering the PRIME scheme • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Review Pathways

More from Agency Leadership